BidaskClub downgraded shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) from a buy rating to a hold rating in a report issued on Thursday morning.
A number of other brokerages also recently weighed in on DPLO. Mizuho increased their price target on shares of Diplomat Pharmacy from $16.00 to $20.00 and gave the company a neutral rating in a report on Tuesday, November 7th. Leerink Swann increased their price target on shares of Diplomat Pharmacy from $16.00 to $20.00 and gave the company a market perform rating in a report on Tuesday, November 7th. TheStreet raised shares of Diplomat Pharmacy from a d+ rating to a c- rating in a report on Thursday, August 10th. Zacks Investment Research raised shares of Diplomat Pharmacy from a hold rating to a strong-buy rating and set a $24.00 price target for the company in a report on Tuesday, October 10th. Finally, Needham & Company LLC reissued a buy rating and issued a $23.75 price target (up from $19.75) on shares of Diplomat Pharmacy in a report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Hold and an average price target of $20.06.
Shares of Diplomat Pharmacy (NYSE DPLO) traded down $0.53 during trading on Thursday, reaching $19.66. 333,700 shares of the company’s stock were exchanged, compared to its average volume of 474,129. The company has a current ratio of 1.34, a quick ratio of 0.88 and a debt-to-equity ratio of 0.18. Diplomat Pharmacy has a 12-month low of $12.25 and a 12-month high of $21.99. The company has a market cap of $1,354.04, a P/E ratio of 25.53, a PEG ratio of 3.54 and a beta of 0.74.
Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings results on Monday, November 6th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.10. Diplomat Pharmacy had a net margin of 0.18% and a return on equity of 8.30%. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same period in the prior year, the firm earned $0.21 EPS. The business’s revenue was down 4.8% on a year-over-year basis. analysts forecast that Diplomat Pharmacy will post 0.85 earnings per share for the current year.
WARNING: This piece was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.chaffeybreeze.com/2017/11/12/diplomat-pharmacy-inc-dplo-cut-to-hold-at-bidaskclub.html.
Several hedge funds have recently made changes to their positions in the company. Frontier Capital Management Co. LLC raised its stake in shares of Diplomat Pharmacy by 4.1% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 5,677,230 shares of the company’s stock valued at $84,023,000 after buying an additional 221,769 shares in the last quarter. BlackRock Inc. raised its stake in shares of Diplomat Pharmacy by 158,977.3% in the 1st quarter. BlackRock Inc. now owns 5,548,617 shares of the company’s stock valued at $88,501,000 after buying an additional 5,545,129 shares in the last quarter. Janus Henderson Group PLC acquired a new position in shares of Diplomat Pharmacy in the 2nd quarter valued at $67,476,000. Vanguard Group Inc. raised its stake in shares of Diplomat Pharmacy by 5.4% in the 2nd quarter. Vanguard Group Inc. now owns 4,077,145 shares of the company’s stock valued at $60,342,000 after buying an additional 210,334 shares in the last quarter. Finally, Davis Selected Advisers raised its stake in shares of Diplomat Pharmacy by 4.4% in the 2nd quarter. Davis Selected Advisers now owns 1,703,992 shares of the company’s stock valued at $25,219,000 after buying an additional 71,846 shares in the last quarter. Institutional investors own 67.36% of the company’s stock.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.